What 4 Analyst Ratings Have To Say About Zoetis
Portfolio Pulse from Benzinga Insights
Four analysts have recently updated their ratings on Zoetis (NYSE:ZTS), with a mix of bullish sentiments. The average 12-month price target is now $216.5, up from $201.67, with a high estimate of $230.00 and a low of $195.00. Analysts from Goldman Sachs, Jefferies, Piper Sandler, and Stifel have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Zoetis, a leader in animal health products, shows strong financial performance with high net margin and ROE, but has a higher debt-to-equity ratio than the industry average.
January 17, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zoetis has received updated ratings from analysts, with an increased average price target of $216.5, indicating a positive outlook. The company's strong financial performance may bolster investor confidence, despite a high debt-to-equity ratio.
The positive revisions in analyst ratings and price targets for Zoetis suggest a bullish sentiment that could lead to a short-term increase in stock price. The company's strong net margin and ROE are likely to be viewed favorably by investors, although the high debt-to-equity ratio may temper some enthusiasm. The overall impact is expected to be positive due to the recent upgrades and the company's solid financial performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100